[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perimenopause\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perimenopause":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,49,97,120,146,176,205,231,248,277,300,333,351,375,414,444,477,506,526,556,580,621,650,678,699],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100644536","cuidar-me-a-web-based-psychological-intervention-for-perimenopausal-women-a-pilot-randomized-controlled-trial-100644536",false,"NCT07672002","Cuidar-ME, a Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trial","A Pilot Randomized Controlled Trial to Evaluate the Acceptability, Feasibility and Preliminary Efficacy of a Web-based Psychological Intervention to Promote Well-being and Mental Health During (Peri)Menopause","Cuidar-ME","Inclusion Criteria:\n\n* Being female;\n* Being between 40 and 60 years old;\n* Being in perimenopause or natural post-menopause;\n* Residence in Portugal;\n* Having access to a computer, tablet, or smartphone and internet (a necessary - condition to complete the program);\n* Being able to read and write in Portuguese.\n\nExclusion Criteria:\n\n* Having menopause induced by medical or surgical reasons;\n* Presence of a severe physical medical condition (self-reported);\n* Presence of a severe psychiatric illness (self-reported);\n* Presence of suicidal ideation.",true,"FEMALE","40 Years","60 Years",{"count":23,"type":24},150,"ESTIMATED","INTERVENTIONAL",[27],"NA","The Cuidar-ME program is a web-based cognitive-behavioral intervention designed to promote well-being and mental health in women during (peri)menopause. The main goal of this research is to evaluate its acceptability, feasibility and preliminary evidence of efficacy of the intervention. This pilot randomized controlled trial uses a two-arm design and serves as a preliminary step before a full-scale RCT.\n\nA sample of at least 150 (peri)menopausal women, aged 40 to 60, will be recruited online. Participants who meet the eligibility criteria will be randomly assigned to either the web-based intervention (Cuidar-ME) or a waitlist control condition (which will receive access to the program after the study concludes).\n\nParticipation in this study will last approximately 3 months. Participants in both conditions will be invited by the researchers via email to complete baseline and post-intervention assessments. These assessments will include self-report questionnaires evaluating several outcomes (e.g., quality of life, menopausal symptoms, depressive and anxiety symptoms, menopause representations, etc.), potential mechanisms of treatment response (emotional regulation and self-compassion), as well as user acceptability and feasibility.",[30,31],"Menopause","Perimenopause",[30,33,34,35,36],"Cognitive-Behavioral Therapy","Web-Based Intervention","Quality of Life","Mental Health","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":24},"2026-09-01",{"date":45,"type":24},"2027-02-01",{"name":47,"class":48},"University of Coimbra","OTHER",{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":18,"sex":19,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100645235","crest-samphire-guided-care-program-on-wellbeing-work-productivity-and-quality-of-life-100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study","18 Years","65 Years",{"count":60,"type":24},50,"OBSERVATIONAL","This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[64,65,66,67,31,30,68],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Dysmenorrhea","Endometriosis","Pelvic Pain",[70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","menopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","RECRUITING","2026-06-25",{"date":88,"type":41},"2026-07-01",{"date":90,"type":41},"2026-06-01",{"date":92,"type":24},"2027-03-01",{"name":94,"class":95},"Samphire Group, Inc.","INDUSTRY",1,{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":19,"minAge":103,"maxAge":21,"enrollmentInfo":104,"targetDuration":4,"studyType":25,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":96},"100625809","amygdala-insula-retraining-in-the-management-of-perimenopause-symptoms-100625809","NCT07427459","Amygdala Insula Retraining in the Management of Perimenopause Symptoms","Inclusion Criteria:\n\n* Experiencing perimenopausal symptoms\n* Meets STRAW+10 criteria based on self-assessment (-2 to +1c)\n* Able to read and understand English\n* Access to internet\n\nExclusion Criteria:\n\n* Pregnancy\n* Presence of a severe psychiatric condition requiring immediate clinical intervention\n* Uncontrolled thyroid disease or prolactinoma\n* Active cancer treatment\n* Inability to provide informed consent\n* Any medical or psychiatric condition that, in the judgment of the investigator or study team, would interfere with safe participation or study completion","38 Years",{"count":105,"type":24},160,[27],"The goal of this study is to evaluate a neuroplasticity-based mind-body intervention, Amygdala and Insula Retraining (AIR), compared to a wait-list control in individuals experiencing perimenopausal symptoms.\n\nOur research questions include:\n\nDoes AIR reduce overall perimenopausal symptom burden compared to a wait-list control?\n\nDoes AIR improve sleep disturbance, vasomotor symptom interference, fatigue, mood, anxiety, and quality of life in perimenopausal individuals?\n\nAre symptom changes associated with improvements in autonomic regulation and sleep parameters, as reflected by exploratory wearable measures including heart rate variability?",[31,109],"Menopausal Complaints",[111],"Amygdala and Insula Retraining (AIR)","2026-06-24",{"date":114,"type":41},"2026-06-29",{"date":116,"type":24},"2026-07-15",{"date":92,"type":24},{"name":119,"class":48},"Chronic Conditions Research Fund",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":127,"targetDuration":4,"studyType":25,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":96},"100639154","evaluation-of-the-effects-of-lifestyle-medicine-and-mindfulness-based-group-medical-visits-on-stress-microbiome-and-quality-of-life-in-women-experiencing-perimenopause-and-menopause-100639154","NCT07619352","Evaluation of the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","A Pilot Study to Evaluate the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","Inclusion Criteria:\n\n1. Biological female.\n2. Age 40 to 60.\n3. Irregular menstruation for 3 months and experiencing perimenopause or menopause as determined by reporting at least one symptom on the Menopause Quality of Life Questionnaire (MENQOL).\n4. Ability to attend group medical visits monthly, in-person for 8 months, at The Ohio State University Center for Integrative Health as well as the baseline and end of study visit.\n5. Ability to participate in the Mindfulness in Motion (MIM) study activities.\n6. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n7. WiFi connectivity or LTE to allow use of MyCap when not at OSU study site\n\nExclusion Criteria:\n\n1. Participants with surgically induced menopause, e.g., hysterectomy, oophorectomy.\n2. Currently receiving or planning to receive hormone therapy for perimenopausal or menopausal symptoms.\n3. Currently taking or planning to take hormonal contraceptives.\n4. Currently taking or planning to take hormone altering medications; i.e. Taxol.\n5. Currently taking probiotics, Siberian rhubarb (Rheum rhaponticum), Black cohosh (Actaea racemosa), Chaste tree berry (Vitex agnus-castus).\n6. Inability to read and\u002For understand English (consent and questionnaires in English).\n7. Current severe alcohol or substance abuse disorder.\n8. Participants with documented cognitive disorder that limits the ability to independently read, understand, and\u002For complete the survey or biological; i.e. dementia, Alzheimer's or biological tests.\n9. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.",{"count":128,"type":24},40,[27],"While perimenopause and menopause are natural biological transitions, women may experience a wide range of physical, emotional, and cognitive symptoms. Although pharmacological options for symptom relief are available, these options may not be acceptable or suitable for all women. Integrative approaches for symptom relief, offered through group medical visits, may complement traditional therapies by increasing access to providers, allowing more time for focused education, and fostering supportive discussions with other women experiencing similar symptoms of perimenopause or menopause.\n\nThe purpose of this study is to assess the effectiveness of eight monthly group medical visits that incorporate individual physical assessments, focused education on the foundational elements of Lifestyle Medicine relative to health and well-being, mindfulness practices, and community-building discussions with women experiencing perimenopause or menopause. Individual outcomes, obtained before the group medical visits begin, at each monthly group medical visit, and four months after the group medical visits are completed, will include measures of participants' perimenopause or menopause symptoms, stress, inflammation, microbiome (good bacteria in the body), height\u002Fweight, body mass index (BMI), systolic and diastolic blood pressure, and self-reported perceptions of physical, mental, and social health.\n\nEach 120-minute monthly group medical visit, led by a specially trained nurse practitioner and a mindfulness instructor, will include a brief physical assessment, educational discussions related to menopause and lifestyle medicine, experiential mindfulness practices, and the development of individual health and well-being goals.",[31,30],[74,75,133,134,135,136],"stress","microbiome","quality of life","women","2026-06-18",{"date":139,"type":41},"2026-06-23",{"date":141,"type":24},"2026-08-01",{"date":143,"type":24},"2028-08-30",{"name":145,"class":48},"Ohio State University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":154,"targetDuration":4,"studyType":25,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":96},"100594660","hemodynamics-after-resistance-training-100594660","NCT07022340","Hemodynamics After Resistance Training","Investigating Resistance Training for Vascular Function and Quality of Life in Perimenopausal Women","HeART","* Are between 40-60 years old\n* Have had menstrual irregularities in the last 12 months\n* Do not currently complete more than two 30-min sessions of structured exercise per week and do not do any resistance training exercise;\n* Are not currently pregnant\n* Do not smoke or vape nicotine or marijuana\n* Have not had an oophorectomy, hysterectomy, or surgical menopause\n* Are not currently taking hormone replacement therapy\n* Have not taken hormone replacement therapy in the last 6 months\n* Are not taking steroidal medication or medication to treat diabetes, cholesterol, or high blood pressure\n* Are able to exercise - your doctor has not told you that you cannot exercise\n* Can attend a morning study visit at the University of Michigan's School of Kinesiology Building\n* Are willing to avoid food 2 hours prior to the morning study visit\n* Are willing to avoid strenuous exercise, caffeine, and alcohol, 8 hours prior to the morning study visit\n* Are willing to participate in an exercise training program or health education program for 16 weeks",{"count":60,"type":24},[27],"Women's blood vessel health gets worse after menopause, or \"the change of life\". Some women exercise less during menopause. Exercise can improve blood vessel health. The investigators want to know if resistance exercise, like lifting weights, can improve blood vessel health in women who are just starting menopause. The investigators also want to know if lifting weights can improve mood, sleep, and quality of life in women going through menopause. The investigators will have two groups of women for this study. One group will lift weights (do resistance exercise) twice per week, and the other group will get emails with information about menopause. The investigators will measure blood vessel health, sleep, mood, and menopause symptoms at the start and the end of this study and compare women who did and did not exercise.",[31],[75,74,159,160,161,162,163,80,164,135,165,166,167],"vascular function","arterial stiffness","endothelial function","resistance exercise training","strength training","sleep","cardiovascular disease","estrogen deficiency","exercise","2026-06-16",{"date":137,"type":41},{"date":171,"type":41},"2025-06-06",{"date":173,"type":24},"2026-12",{"name":175,"class":48},"University of Michigan",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":96},"100642640","cognitive-task-sensitivity-in-perimenopause-and-nutritional-status-100642640","NCT07648667","Cognitive Task Sensitivity in Perimenopause and Nutritional Status","Pilot Study Assessing Cognitive Task Sensitivity in Perimenopause and Its Association With Nutritional Status","Inclusion Criteria:\n\n* Aged 40-55 years\n* Self-assess as healthy\n* Experienced troublesome perimenopause symptoms for at least the past 6 months (as assessed by the Menopause Rating Scale)\n* Not post-menopause (defined as 12 months with no periods)\n* Non-smoker (including vaping)\n* Not lactating or pregnant (or seeking pregnancy)\n* Oral contraception and hormone replacement therapy allowed if taken for at least 3 months prior\n* Cognitive symptoms\u002Fbrain fog are not required for participation\n\nExclusion Criteria:\n\n* Post-menopause (12 months with no periods)\n* Medically induced perimenopause symptoms\n* Antidepressant\u002Fantianxiety medication or other medication likely to affect cognition in the past 6 months\n* Receiving gender-affirming hormone therapy\n* Nutritional supplementation (apart from vitamin D) within the last month (more than 3 consecutive days or 4 total)","55 Years",{"count":185,"type":24},60,"Perimenopause is when you have symptoms of menopause but your periods have not stopped. Brain-related changes are just one of the many symptoms that occur, and changes to memory and concentration (\"brain fog\") are frequently reported to be a challenge to those experiencing them. Diet is also understood to play an important role during menopause, however there is still more to learn about the direct impact of nutrition on brain-related symptoms associated with perimenopause. The aim of this research is to identify mental tasks capable of capturing perimenopause-related changes and to better understand how diet might account for differences in mental task performance.",[31,188],"Cognitive Function in Perimenopause",[31,190,191,192,193,194,195],"Cognitive Function","Brain Fog","Diet","Nutrition","Food Frequency Questionaire","Menopause Rating Scale","2026-06-12",{"date":198,"type":41},"2026-06-15",{"date":200,"type":24},"2026-06",{"date":202,"type":24},"2026-07",{"name":204,"class":48},"Northumbria University",{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":212,"targetDuration":4,"studyType":25,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":96},"100611580","12-week-multi-vitaminmineral-supplementation-on-peri-menopause-symptoms-cognition-sleep-and-psychological-well-being-100611580","NCT07242430","12-week Multi-vitamin\u002FMineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being.","Effects of 12-week Multi-vitamin\u002FMineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep and Psychological Wellbeing - a Randomised, Placebo-controlled Trial","Inclusion Criteria:\n\n* Self-assess as healthy\n* Report experiencing troublesome peri-menopause symptoms in the past 6 months but not post-menopausal (defined as 12 months with no periods)\n\nExclusion Criteria:\n\n* Post-menopausal\n* Lactating, pregnant or seeking to become pregnant\n* Nut Allergy\n* Taken antidepressant\u002Fantianxiety medication or other medication with strong likelihood for effects on cognition or sleep in the past 6 months.\n* Habitual multi-vitamin\u002Fmineral supplementation (defined as more than 3 consecutive days or 4 days in total). Will be excluded unless washout for 1 month.\n* Menopause symptoms have been medically induced.\n* Receiving gender-affirming hormone therapy.",{"count":213,"type":24},58,[27],"Perimenopause is a stage of transition into menopause that is marked by menopausal symptoms while menstruation is still taking place. Perimenopause symptoms include mood changes, anxiety, sleep disruptions, hot flushes, night sweats, fatigue, and cognitive challenges. The frequency and severity of these symptoms can seriously impair women's quality of life. Even if the public's awareness on menopause has increased, there are still a lot of unanswered questions. A connection between nutrition and menopause management has been proposed in earlier research. However, there is limited research in this field, and women frequently turn to social media for supplement recommendations in order to deal with menopause-related issues.\n\nVitamins and minerals such as vitamin D and calcium are recommended by the European Menopause and Andropause Society and there is limited evidence to suggests that soy and herbals may have a beneficial effect on menopausal symptoms, but more research is needed.\n\nThe aim of this study is to investigate the effects of 12-weeks multi-vitamin\u002Fmineral and herbal extract-containing supplement on menopause symptoms, memory and concentration, sleep, and psychological well-being.",[31,217,218],"Perimenopausal Women","Perimenopause, Climacteric Syndrome",[74,220,221,164,222,223],"cognition","psychological wellbeing","magnesium","memory","2026-05-28",{"date":226,"type":41},"2026-05-29",{"date":228,"type":41},"2026-04-07",{"date":141,"type":24},{"name":204,"class":48},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":238,"targetDuration":4,"studyType":25,"phases":239,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":96},"100611076","12-week-magnesium-supplementation-on-peri-menopause-symptoms-cognition-sleep-and-psychological-well-being-100611076","NCT07235878","12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being","Effects of 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep and Psychological Wellbeing - a Randomised, Placebo-controlled Trial","Inclusion Criteria:\n\n* Self-assess as healthy\n* Report experiencing troublesome peri-menopause symptoms in the past 6 months but not post-menopausal (defined as 12 months with no periods)\n\nExclusion Criteria:\n\n* Post-menopausal\n* Lactating, pregnant or seeking to become pregnant\n* Nut Allergy\n* Taken antidepressant\u002Fantianxiety medication or other medication with strong likelihood for effects on cognition or sleep in the past 6 months.\n* Habitual magnesium supplementation (defined as more than 3 consecutive days or 4 days in total). Will be excluded unless washout for 1 month.\n* Menopause symptoms have been medically induced.\n* Receiving gender-affirming hormone therapy.",{"count":213,"type":24},[27],"Perimenopause is a transition phase into menopause, characterised by menopausal symptoms while menstrual periods are still occurring. Common symptoms of perimenopause include hot flushes, night sweats, mood swings, anxiety, sleep disturbances, fatigue, and cognitive difficulties. These symptoms can be both frequent and intense, with the potential to significantly deteriorate women's quality of life. Despite an increase in public discourse around menopause, there are still large gaps in knowledge. Previous literature has suggested a relationship between diet and menopause management. However, studies in this area are limited and women often rely on social media for advice on supplements to address menopause complaints. One supplement that has received a lot of attention with purported benefits for menopause is magnesium, primarily due to its links to energy and or\u002Fsleep, however no studies have explored psychological effects of magnesium supplementation in perimenopause.\n\nThe aim of this study is to explore the effects of 12-weeks magnesium supplementation on perimenopause symptoms, cognition, sleep, and psychological well-being.",[31,217,218],[74,220,221,164,222,223],{"date":226,"type":41},{"date":245,"type":41},"2025-12-09",{"date":141,"type":24},{"name":204,"class":48},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":256,"targetDuration":4,"studyType":25,"phases":258,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":96},"100638243","impact-of-a-novel-functional-snack-on-perimenopausal-symptoms-and-well-being-100638243","NCT07599930","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial","SWAP","Inclusion Criteria:\n\n* Adults aged 40 to 55\n* Score 14 or higher on the Menopause Rating Scale\n* For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.\n\nExclusion Criteria:\n\n* People who consume more than 15g of fibre a day\n* People who consume more than 2 cups of coffee or tea a day\n* People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day\n* People who do not have any intolerances or allergies to the following:\n* Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts\n* Chia seeds\n* Pumpkin seeds\n* Sunflower seeds\n* Dates\n* Gluten\n* Dairy\n* Oats\n* Barley\n* Soya\n* People who smoke or vape or have smoked or vaped in the last 2 years\n* People who consume more than 21 drinks a week or have a history of excess alcohol intake\n* People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems\n* People receiving drug treatment for lipid metabolisms (e.g., statins)\n* People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin\n* People taking antihypertensive drugs\n* People who take antibiotics or bacterial agents (Probiotics) within 1 month\n* People who take vitamin\u002Fdietary supplements within 1 month\n* Pregnant women, women ready for pregnancy, and nursing mothers\n* cardiac arrhythmia\n* renal failure\n* heart failure (NYHA II-IV)\n* diabetes mellitus\n* Malignant disease\n* People who have participated in a biomedical study within the past 3 months\n* Women who require hormone replacement therapy during the development of the protocol.",{"count":257,"type":24},20,[27],"This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.\n\nHypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.\n\nMain research questions:\n\nDoes eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?",[31,261,262,263,35,264],"Perimenopause-Related Depression","Mood","Sleep","Gut -Microbiota",[266,267,80,164,135,268],"phytochemical","fibre","gut","2026-05-14",{"date":271,"type":41},"2026-05-20",{"date":273,"type":41},"2026-04-24",{"date":173,"type":24},{"name":276,"class":48},"King's College London",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":19,"minAge":283,"maxAge":183,"enrollmentInfo":284,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100637622","our-transitions-improving-the-path-to-menopause-with-personal-digital-health-technologies-100637622","NCT07597915","Our Transitions: Improving the Path to Menopause With Personal Digital Health Technologies","Inclusion Criteria:\n\n* Are 35-55 years old\n* Reside in the US or Canada\n* Are able to speak, write, and read English\n* Are able to provide informed consent\n* Have a personally owned iPhone (iOS Version 16.4)\n\nExclusion Criteria:\n\n* Are not willing to wear a wearable study device\n* Have a hormonal intrauterine device (IUD)\n* Are taking birth control pills\n* Are taking systemic estrogen or progesterone\n* Have been diagnosed with Polycystic ovary syndrome (PCOS)\n* Are taking the following medications (cancer treatment that affects the menstrual cycle, thyroid medication)\n* Have had the following procedures (hysterectomy \\[removal of uterus\\], bilateral, oophorectomy \\[removal of both ovaries\\], endometrial ablation \\[surgery that destroys the lining of the uterus\\])\n* Are currently pregnant, attempting to conceive, recently pregnant and not yet cycling and currently breast feeding","35 Years",{"count":285,"type":24},1250,"The goal of this observational study is to build knowledge about the path to menopause using subjective, self-reported and objectively measured information from multiple wearable study devices and a smartphone app. This study is being done in female individuals who are 35-55 years of age. The eventual aim of this work is two-fold; 1) to increase knowledge, awareness and education for individuals and clinicians about the lived experience of perimenopause and menopause through objectively measured data from digital study devices, and 2) to develop approaches to empower female individuals to manage this transition by learning what improves or worsens their symptoms.",[31,30],[31,30,289,290,291,292],"Menopause Transition","Wearables","Oura","Fitbit",{"date":271,"type":41},{"date":295,"type":24},"2026-05-01",{"date":297,"type":24},"2027-08-31",{"name":299,"class":48},"4YouandMe",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":19,"minAge":308,"maxAge":21,"enrollmentInfo":309,"targetDuration":4,"studyType":25,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":96},"100641020","probiotic-intake-and-perimenopausal-psychological-assessments-100641020","NCT07590999","Probiotic Intake and Perimenopausal Psychological Assessments","The Effects of a Probiotic on Emotional Processing, Cognition, and the Gut Microbiome in Perimenopausal Women","PIPPA","Inclusion Criteria:\n\n* Female at birth\n* You are aged 45-60 years and in perimenopause (determined by changes in menstrual bleeding patterns (such as changes in cycle length of 7 days or longer in either direction from what is normal for you), AND vasomotor symptoms (e.g., hot flushes and sweats) AND mild to moderate mood or cognitive disturbances, or joint and muscle pain over the previous 12 months)\n* You are willing and able to give informed consent for participation in the study\n* You are sufficiently fluent in English to understand and complete tasks\n* You are at least 12 months post-natal\n* Willing to withhold from having grapefruit juice\n\nExclusion Criteria:\n\n* Currently receive or seek treatment for any mental health condition\n* Have a BMI \\>=30 OR \\\u003C=18.5\n* Have lost or gained more than 10% of body weight in a short period (e.g., 6 months), as this can affect mood and cognition\n* Currently using hormonal contraception or have used hormonal contraception in the last 6 months\n* Have had gender reassignment surgery or gender-affirming hormone therapy\n* Had a head injury causing concussion or unconsciousness in the past 6 months\n* Participated in other studies that may influence mood, cognition, or gut health in the last three months\n* Are currently diagnosed with and\u002For treated for psychiatric or neurological disorders\n* Are on perimenopausal hormone replacement therapy (HRT) (e.g., estrogen, progesterone, testosterone) or other hormone-modulating medications (e.g., GLP-1 agonists, thyroxine replacement), as these can impact mood and cognitive functions\n* Currently use statins or have used statins in the last 6 months, as these may impact mood and cognitive functions\n* Participated in any other study with the same tasks in the last year\n* Currently use medications that influence cognition or mood, such as antidepressants, anxiolytics, antipsychotics, stimulants, mood-stabilizers, or cognitive-enhancing drugs\n* Have chronic or severe gastrointestinal diseases (e.g., inflammatory bowel disease, Crohn's disease, celiac disease, or severe acid reflux; treatment with e.g., corticosteroids, antacids), as these conditions and treatments can affect the gut microbiota and immune responses differently from healthy individuals\n* Have a compromised immune system\n* Currently smoke, vape, or use any other nicotine products\n* Have a current diagnosis of cognitive impairment or neurodegenerative disorders (e.g., mild cognitive impairment, dementia), as these conditions could confound cognitive assessments.\n* Have severe medical conditions requiring ongoing medication that may independently affect cognition or mood (e.g., diabetes)\n* Currently or recently used antibiotics (last 3 months), as antibiotics may alter gut microbiota and interfere with probiotic effects\n* Currently or recently used probiotics or prebiotics or consumed fermented products (e.g., kimchi, kombucha, sauerkraut, kefir, etc.) on a regular basis (last 3 months), which might interfere with the study intervention\n* Have known allergies or intolerances to probiotics or components in the probiotic supplement.\n* Have substance abuse or dependence (e.g., alcohol, recreational drugs) that may affect mood and cognition.\n* Have Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (Long COVID)\n* Have had a hysterectomy\n* Are pregnant or lactating, as hormonal changes associated with these states could confound results.\n* Score of 20 or above on PHQ-9 depression questionnaire, indicating severe depression\n* Score of \\>1 on PHQ-9 suicidality item, indicating significant suicidality (as assessed by medical on-site professionals","45 Years",{"count":310,"type":24},106,[27],"Recent evidence suggests multi-strain probiotics containing Lactobacillus rhamnosus and Bifidobacterium longum have been found to enhance emotional processing and reduce salience to negative cues in studies involving people with mood disorders, as well as improve cognitive functions, such as memory and concentration, in healthy participants. By administering computer-based tasks, questionnaires and checking biological measures (cortisol, immune markers, blood metabolites, gut microbiota) using blood and faecal samples, this experimental medicine study aims to investigate whether a probiotic supplement has an effect on emotional processing and cognition in perimenopausal women. We also aim to study changes in gut bacteria from stool samples before and after taking the supplement to see if any microbiome changes are associated with any effects in emotional processing, cognitive function, and biological markers.",[314,31,261,217],"Emotional Processing and Cognitive Function in Perimenopausal Women Experiencing Cognitive Perturbations",[74,75,316,317,318,319,320,321,322,323],"gut microbiome and perimenopause","cognition and perimenopause","emotional processing and perimenopause","mood and perimenopause","gut microbiome and cognition","probiotics","probiotic","gut microbiome","2026-05-12",{"date":326,"type":41},"2026-05-15",{"date":328,"type":41},"2025-11-12",{"date":330,"type":24},"2027-06-30",{"name":332,"class":48},"University of Oxford",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":340,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":96},"100636826","occupational-disruption-and-role-strain-during-perimenopause-100636826","NCT07570732","Occupational Disruption and Role Strain During Perimenopause","Occupational Disruption and Role Strain During Perimenopause: A Mixed-Methods Study","Inclusion Criteria:\n\n* Women aged 40-55\n* Self-reported perimenopausal symptoms\n* Currently employed (paid or unpaid) or managing household roles\n* English-speaking\n\nExclusion Criteria:\n\n* Surgical menopause\n* Current pregnancy",{"count":341,"type":24},100,"The purpose of this sequential exploratory mixed-methods study is to examine the relationship between perimenopausal symptom severity and occupational performance, occupational balance, and role participation in women aged 40-55. A secondary purpose is to explore the lived experience of occupational disruption during perimenopause through qualitative interviews.",[31],{"date":345,"type":41},"2026-05-06",{"date":90,"type":24},{"date":348,"type":24},"2027-05-01",{"name":350,"class":48},"Russell Sage College",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":359,"targetDuration":4,"studyType":25,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":96},"100613867","exercise-in-perimenopause-to-improve-cognitive-health-100613867","NCT07272174","Exercise in Perimenopause to Improve Cognitive Health","Resistance Training and Cognitive Health in Perimenopause","EPIC","Inclusion Criteria:\n\n* Are biological females, as assigned at birth\n* Are aged between 40 and 55 years\n* Had at least 1 menstrual period in the last 10 months\n* Are perimenopausal based on STRAW +10 Staging System, or answer \"yes\" to MQ6 questions of changes in periods, having hot flashes, or vaginal dryness, pain, or sexual concerns\n* Have an intact uterus\n* Have a Montreal Cognitive Assessment (MoCA) score \\>26\u002F30, indicating normal cognition\n* Have subjective cognitive complaints defined as responding \"yes\" to \"Do you feel like your memory or thinking is becoming worse?\"\n* Completed high school education\n* Read and speak English with acceptable visual and auditory acuity\n* Are able to safely engage in moderate-intensity PRT as indicated by the PAR-Q+; and\n* Are able to provide informed consent.\n\nExclusion Criteria:\n\n* Are engaged in regular PRT (i.e., 2x\u002Fweek) in the prior three months\n* Are diagnosed with cognitive impairment or dementia of any type\n* Are at high risk for cardiac complications during exercise\n* Have clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility\n* Are taking medications that negatively affect cognitive function, such as anticholinergics, major tranquilizers, and anticonvulsants\n* Have a BMI \\\u003C15 or anorexia nervosa; g) had surgical menopause\n* Had endometrial ablation that resulted in the loss of menstruation\n* Have polycystic ovarian syndrome\n* Currently undergoing chemo\n* Are using estrogen-containing contraception in the last 12 months\n* Had premature ovarian failure; or\n* Are already enrolled in a drug or exercise trial",{"count":60,"type":24},[27],"Perimenopause is now considered a possible risk factor for dementia and may contribute to the fact that 2\u002F3 of those living with Alzheimer's disease are females. Indeed, research studies show that middle-aged females demonstrate significant declines in their thinking abilities and detrimental changes in their brains as they go through perimenopause. Thus, perimenopausal females need strategies to bolster their brain health.\n\nThe World Health Organization strongly recommends physical activity interventions to reduce the risk of decline in thinking abilities. However, whether exercise can improve thinking abilities and brain health in perimenopausal females has not been examined. Our research aims to address this important knowledge gap in female brain health.\n\nWe will study the effects of a 6-month resistance exercise training (e.g., lifting free weights, exercise with weight machine) program on thinking abilities in 50 physically inactive perimenopausal females, aged 40 to 55 years, who are experiencing difficulties with their thinking abilities. In addition to measuring thinking abilities, we will determine if exercise benefits muscle health, heart health, sleep quality, psychological well-being, menopausal symptoms, and quality of life. We will also explore how resistance exercise training improves thinking abilities as such information can lead to new discoveries and therapies for brain health in females.",[31,363],"Subjective Cognitive Complaints",[365],"progressive resistance training, perimenopause","2026-04-13",{"date":368,"type":41},"2026-04-16",{"date":370,"type":41},"2026-03-30",{"date":372,"type":24},"2027-01-30",{"name":374,"class":48},"University of British Columbia",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":25,"phases":385,"briefSummary":387,"conditions":388,"keywords":394,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":410,"leadSponsor":412,"locationsCount":96},"100633458","phase-4-vaginal-estradiol-vs-moisturizer-to-improve-postmenopausal-vaginal-aging-symptoms-and-the-microbiome-in-women-living-with-hiv-100633458","NCT07526948","Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV","Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV","Inclusion Criteria:\n\n* female\n* at least 40 years old\n* menopausal (no menses in 12 months) within 2 years of last menstrual period or perimenopausal in the late menopausal transition, defined as an interval of amenorrhea greater than or equal to 60 days\n* have symptoms of the genitourinary syndrome of menopause (GSM) which developed within the prior 2 years. Symptoms of GSM include vaginal symptoms including dryness, soreness, itching, irritation and dyspareunia and\u002For urinary symptoms including urgency, frequency and recurrent urinary tract infections (UTIs)\n\nExclusion Criteria:\n\n* Unexplained or unevaluated abnormal genital bleeding\n* Current or suspected pregnancy\n* Desired pregnancy\n* If less than 55 years old, have had a hysterectomy and have at least one ovary (as menopause cannot be determined in this case by amenorrhea alone)\n* Pelvic or vaginal surgery in the prior 60 days\n* Used systemic reproductive hormones in the last 2 months\n* Used antibiotics in the last 30 days\n* Used immunosuppressive medications in the prior 60 days including biologics, chemotherapeutics or post transplant immunosuppressive medications\n* Used any vaginal or vulvar preparations in the last month\n* Current active vaginal infection diagnosed at study entry\n* Any serious disease or condition that may interfere with study compliance\n* Current or previous history of breast cancer or estrogen dependent cancer (e.g., ovarian, endometrial)\n* Current or previous history of deep vein thrombosis or pulmonary embolism\n* Current or previous history of myocardial infarction or stroke\n* Known clotting disorder including Protein C, Protein S and antithrombin deficiency, Factor V Leiden or prothrombin mutations\n* Known severe liver disease including cirrhosis or active Hepatitis B\n* Known allergic reaction to Vagifem (estradiol vaginal tablet) or Replens","70 Years",{"count":384,"type":24},62,[386],"PHASE4","This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.",[109,389,390,391,392,393,31],"Vaginal Atrophy","Genitourinary Symptoms","HIV (Human Immunodeficiency Virus)","Menopause Related Conditions","Vaginitis",[395,396,397,398,30,399,400,401,402,403,404,405],"Pain with sex","Vaginal dryness","Symptoms of menopause","HIV Infection","Vaginal microbiome","Dysbiosis","Aging","Premature aging","Atrophic vaginitis","Genitourinary syndrome of menopause (GSM)","Symptoms of perimenopause","2026-04-08",{"date":408,"type":41},"2026-04-14",{"date":90,"type":24},{"date":411,"type":24},"2031-06-30",{"name":413,"class":48},"Albert Einstein College of Medicine",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":19,"minAge":308,"maxAge":183,"enrollmentInfo":421,"targetDuration":423,"studyType":61,"phases":4,"briefSummary":424,"conditions":425,"keywords":428,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":4},"100631170","amh-dynamic-changes-to-predict-ovarian-reserve-in-perimenopausal-breast-cancer-100631170","NCT07497191","AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients","Inclusion Criteria:\n\n1. Female, aged 45-55 years\n2. Histologically confirmed hormone receptor-positive breast cancer\n3. Perimenopausal status defined as: (a) last menstrual period within 3 months prior to enrollment; and (b) FSH 10-40 IU\u002FL and E2 \\>20 pg\u002FmL\n4. Scheduled to receive adjuvant chemotherapy and\u002For endocrine therapy\n5. Willing to undergo serial blood sampling and complete menstrual diaries\n6. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Postmenopausal status\n2. Prior bilateral oophorectomy or pelvic radiotherapy\n3. Severe hepatic or renal dysfunction\n4. Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative breast cancer\n5. Conditions affecting ovarian hormone secretion (e.g., ovarian tumors, polycystic ovary syndrome, pituitary tumors)\n6. Current pregnancy, lactation, or planned pregnancy during follow-up\n7. Use of hormonal intrauterine devices\n8. Prior use of GnRH agonists or aromatase inhibitors",{"count":422,"type":24},300,"3 Years","This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone receptor-positive breast cancer.\n\nThe study will enroll approximately 300 women aged 45-55 years with perimenopausal status confirmed by menstrual history and hormone levels (FSH 10-40 IU\u002FL, E2 \\>20 pg\u002FmL). Participants will be stratified by treatment regimen: (A) chemotherapy plus endocrine therapy, (B) chemotherapy plus targeted therapy plus endocrine therapy, and (C) endocrine therapy alone.\n\nBlood samples will be collected at seven time points to measure AMH, FSH, E2, and LH. Menstrual patterns and menopausal symptoms will be recorded prospectively. The primary outcome is the association between dynamic AMH changes and the occurrence of menopause. A predictive model will be constructed using LASSO regression and Cox proportional hazards models, with internal validation by bootstrap resampling.\n\nThe goal is to develop a clinically applicable tool to guide endocrine therapy decisions-including the duration of ovarian function suppression (OFS), choice between tamoxifen and aromatase inhibitors (AIs), and selection of CDK4\u002F6 inhibitors-as well as to provide individualized fertility preservation counseling for perimenopausal breast cancer patients.",[426,31,427],"Breast Cancer","Ovarian Reserve",[429,427,430,431,432,433,434],"Anti-Müllerian Hormone","Perimenopausal Breast Cancer","Dynamic Monitoring","Predictive Model","Endocrine Therapy","Chemotherapy-Induced Amenorrhea","2026-03-23",{"date":437,"type":41},"2026-03-27",{"date":439,"type":24},"2026-03-05",{"date":441,"type":24},"2030-03-05",{"name":443,"class":48},"Shengjing Hospital",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":451,"targetDuration":4,"studyType":25,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":96},"100603339","the-effects-of-resistance-training-and-a-plant-based-supplement-on-perimenopausal-symptoms-and-muscle-health-100603339","NCT07135232","The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.","The Effects of Resistance Training and a Sarmentosin - L-theanine Supplement on Perimenopausal Symptoms and Musculoskeletal Health: A Randomised Controlled Trial","Inclusion criteria\n\n1. Perimenopausal women between 40 - 55 years\n2. Not currently engaging in consistent structured resistance training (defined as \\>3 resistance training sessions per week for 4 consecutive weeks, in the past six months).\n3. Not on any HRT or hormonal contraception for at least one year before initiation of the study.\n4. Able to attend laboratory visits and commit to the intervention schedule for 6 months.\n5. Willing to provide blood samples\n6. Not regularly consuming any dietary supplements containing concentrated sarmentosin, L-theanine or other compounds that may interfere with the study intervention.\n7. Willing to limit dietary intake of Sarmentosin (e.g. Blackcurrant) and L-theanine (e.g. green tea\u002F black tea).\n8. Willing and able to provide written informed consent\n\nExclusion criteria\n\n1. Diagnosed cardiovascular disease (CVD), uncontrolled hypertension (\\>160\u002F100 mmHg), or other conditions that prevent safe exercise participation.\n2. Clinically diagnosed mental health disorders (e.g., bipolar disorder, schizophrenia, severe depression requiring medication adjustment within the last 6 months).\n3. Neurological conditions affecting cognitive function (e.g., Parkinson's disease, multiple sclerosis, epilepsy).\n4. Endocrine disorders that could impact hormonal fluctuations or metabolism (e.g., uncontrolled diabetes, thyroid dysfunction).\n5. History of major musculoskeletal injuries (e.g., fractures, joint replacement) within the past 6 months\n6. Regular use of medications that could interfere with study outcomes, including antidepressants, corticosteroids, beta-blockers.\n7. Obesity (BMI \\>30 or for South Asian Ethinicity BMI\\> 27.5)\n8. Food allergy or intolerance to study products.\n9. Use of illicit drugs.\n10. Alcohol intake exceeding the government guidelines of 14 standard units per week (Equivalent of 6 standard drinks).\n11. Pregnant or planning to conceive during the trial.\n12. High habitual caffeine intake (\\>400 mg\u002Fday which is approximately 4-5 cups of coffee)",{"count":452,"type":24},72,[27],"The aim of this clinical trial is to determine if resistance training and a newly developed plant-based nutritional supplement can improve the symptoms and musculoskeletal health of perimenopausal women.\n\nThe main questions it aims to evaluate are:\n\n1. Can resistance training and the nutritional supplement - both independently and in combination - improve perimenopausal symptoms (e.g. cognition, mood, sleep) and musculoskeletal outcomes (e.g. strength, muscle mass)?\n2. What are the acute effects of the nutritional supplement on cognitive function and mood in perimenopausal women, and is this response altered following long-term intake (12 weeks)?\n3. What mechanisms may be contributing to the results?\n\nParticipants will be split into four groups to allow the researchers to answer the above questions. These are:\n\n1. The nutritional supplement + resistance training\n2. The nutritional supplement only\n3. The placebo supplement (A look alike capsule that contains no active ingredients) and resistance training\n4. The Placebo supplement only.\n\nParticipants will:\n\n* Take their allocated supplement daily and perform home-based strength exercise 3 times per week (for exercise groups), for 12 weeks.\n* Attend the laboratory at the beginning and end of the 12 weeks to assess cognitive function and mood following acute intake of the supplement.\n* Attend the laboratory every 4 weeks during the 12 week period, for assessment of cognitive function, symptom severity and muscle health.\n* Provide a blood sample at each visit for assessment of mechanistic pathways.",[31,30],[262,457,458,459,460,461,462,75,463,464,465,167,74,466,467,468,469,133],"Depression","Cognition","Resistance Training","Sarmentosin - L-theanine","Bioactive supplement","perimenopause symptoms","lifestyle","muscle","health","symptoms","hot flashes","vasomotor","anxiety",{"date":437,"type":41},{"date":472,"type":24},"2026-03-01",{"date":474,"type":24},"2027-04-01",{"name":476,"class":48},"Leeds Beckett University",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":18,"sex":19,"minAge":308,"maxAge":183,"enrollmentInfo":484,"targetDuration":4,"studyType":25,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":96},"100629300","multi-acupoint-laser-therapy-for-body-shape-and-composition-in-obese-menopausal-women-100629300","NCT07472881","Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women","Effects of a Multi-acupoint Laser Therapy Device on Body Shape and Body Composition in Obese Menopausal Women","Inclusion Criteria:\n\n* Female participants aged 45 to 55 years\n* No cognitive impairment or major psychiatric disorder\n* Able to understand the study procedures and communicate with research staff\n* Body mass index (BMI) \\> 24 kg\u002Fm² OR waist-to-hip ratio \\> 0.88\n\nExclusion Criteria:\n\n* Pregnant or possibly pregnant women\n* Diagnosed chronic diseases currently under active treatment, including hepatitis, chronic kidney disease, chronic gastrointestinal disease, cardiovascular disease, or cancer\n* Systemic diseases such as hyperthyroidism, hypothyroidism, compensated liver cirrhosis, or autoimmune disorders\n* Currently receiving weight control treatment, including bariatric surgery or weight-loss medications\n* History of epilepsy or seizure disorder\n* Coagulation disorders or current use of anticoagulant therapy",{"count":128,"type":24},[27],"The purpose of this study is to integrate Traditional Chinese Medicine (TCM) theory and therapeutic methods with modern low-level laser stimulation on corresponding acupoints, applying this combined approach to the field of weight management in menopausal women. The trial aims to investigate whether lifestyle modifications in accordance with WHO guidelines (dietary control and exercise), combined with adjunctive low-level laser acupuncture, can enhance weight reduction and improve body composition more effectively than standard lifestyle interventions alone.",[30,31,488,489],"Obesity","Overweight",[491,492,488,30,493,494,495,496],"Laser acupuncture","Low-level laser therapy","Body composition","Weight management","Acupoint stimulation","Randomized controlled trial","2026-03-18",{"date":499,"type":41},"2026-03-20",{"date":501,"type":41},"2026-03-16",{"date":503,"type":24},"2029-01-24",{"name":505,"class":48},"Chang Gung Memorial Hospital",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":18,"sex":19,"minAge":308,"maxAge":183,"enrollmentInfo":512,"targetDuration":4,"studyType":25,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":96},"100629964","impact-of-intermittent-fasting-on-the-mental-health-of-perimenopausal-women-100629964","NCT07481513","Impact of Intermittent Fasting on the Mental Health of Perimenopausal Women","Inclusion Criteria:\n\n* Participants eligible in this study will be women between the ages of 45 and 55 who are in the perimenopausal stage as defined by the STRAW criteria and confirmed using the Menopausal Rating Scale (MRS).\n\nExclusion Criteria:\n\n* Currently using hormone replacement therapy\n* Diagnosed with severe medical conditions that could interfere with fasting, including uncontrolled diabetes, heart disease, hypertension, cancer or kidney disease\n* Have a current formal mental health diagnosis as defined by the DSM-5, regardless of whether they are receiving medication or therapy\n* Experiencing any form of dementia\n* Have undergone surgical menopause, have premature ovarian failure, are currently undergoing chemotherapy or radiotherapy, or are ovarian cancer survivors\n* Are currently pregnant. undergoing treatment for endometriosis, have significant thyroid disorders, or are on any form of hormone therapy\n* Do not speak English\n* Participants who score greater than 0 on question 9 of the PHQ-9 (including suicidal ideation) will be removed from the trial and provided with mental health referrals to NGOs for support.",{"count":513,"type":24},140,[27],"This study will explore how intermittent fasting (specifically the 16\u002F8 method) affects the mental health of women who are in the perimenopause stage. This life stage often brings hormonal changes that can impact emotional and physical well-being. The study will include 98 women aged 45-55, who will be randomly divided into two groups. The study will compare the mental health outcomes of those who follow intermittent fasting with those who do not, using independent t-tests to analyze the results. The goal is to better understand if intermittent fasting can help improve mental health during perimenopause.",[36,31,517],"Intermittent Fasting",[517,36,31,457],{"date":520,"type":41},"2026-03-19",{"date":522,"type":41},"2025-09-23",{"date":173,"type":24},{"name":525,"class":48},"American University of Beirut Medical Center",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":532,"targetDuration":4,"studyType":25,"phases":534,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":96},"100623210","phase-2-effects-of-hemp-derived-cannabinoids-on-menopause-symptoms-100623210","NCT07393672","Effects of Hemp-Derived Cannabinoids on Menopause Symptoms","Inclusion Criteria:\n\n* designated female at birth\n* 40-60 years of age\n* able to give informed consent (no intellectual disability)\n* stable pharmacotherapeutic regimen, no change in the past 3 months\n* abstinent from regular cannabis use (\\\u003C1x\u002Fmonth) for past year, and willing to abstain from use for 3 months\n* abstinent for supplements, don't add any supplements (no changes in past 3 months)\n* own a smartphone\n* have access to Zoom on a secure, stable internet connection\n* perimenopausal or menopausal\n\nExclusion Criteria:\n\n* currently taking anti-depressant, anti-anxiety, and\u002For antipsychotic medication\n\n  * severe depression, neurovegetative symptoms, or current suicidality\n  * psychosis or family history of psychosis\n  * pregnant or breastfeeding\n  * chemotherapy\n  * hypotension\n  * drug testing for work or other reasons\n  * illicit drug use in past 3 months (cannabis not illicit)\n  * heavy alcohol use (4 drinks more than 4x\u002Fweek)\n  * international\u002Fair travel planned for more than one week in the next 3 months\n  * cocounut allergy",{"count":533,"type":24},104,[535],"PHASE2","The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause\u002Fperimenopause.",[30,31],[30,31,539,540,541,542,458,543,263,262,544,545,546],"Cannabinoids","CBG","CBD","Hemp-derived THC","Anxiety","Pain","Stress","Brain fog","2026-03-06",{"date":549,"type":41},"2026-03-10",{"date":551,"type":41},"2026-02-11",{"date":553,"type":24},"2026-11-10",{"name":555,"class":48},"Washington State University",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":308,"enrollmentInfo":563,"targetDuration":4,"studyType":25,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":96},"100626859","shatavari-root-extract-for-perimenopausal-symptoms-100626859","NCT07441109","Shatavari Root Extract for Perimenopausal Symptoms","Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract for Treatment of Perimenopausal Symptoms in Women: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study","Inclusion Criteria:\n\n1. Menopausal women aged \\>40 to 45 years with intact uterus and ovaries.\n2. Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months or reported menopause for at least 60 days.\n3. Females with complaints of at least two of the menopausal symptoms, e.g., hot flashes, night sweats, mood swings, sleep disturbance, breast tenderness\n4. Body mass index 18-35 kg\u002Fm2\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study.\n6. Able to read and write in English or any other vernacular language.\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to si\n\nExclusion Criteria:\n\n1. Participants taking any form of herbal extract in the last 3 months before study entry.\n2. Participants who are on hormone replacement therapy (HRT) for more than 3 months.\n3. Participants who are pregnant.\n4. Participants with present active medical, surgical, and gynaecological problems.\n5. Participants with a history of alcohol, tobacco dependence, or any substance abuse.\n6. Participants who had undergone bilateral ovariectomy\n7. Participants with history of breast or cervical carcinoma\n8. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate.\n9. Participants with clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study result difficult.\n10. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n11. Participants with evidence of demonstrated inability to follow study protocols or attend follow-up visits, including poor compliance.\n12. Participants with demonstrated inability to follow study protocols or attend follow-up visit\n13. Participants with inability to attend follow-up visit\n14. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective.\n15. Patients who had participated in other clinical trials during the previous 3 months.\n16. Patients who have any clinical condition, according to the investigator, who does not allow safe fulfilment of clinical trial protocol.",{"count":185,"type":24},[27],"This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.",[31,567],"Women Health",[569,570],"Shatavari","Dietary Supplement","2026-02-28",{"date":573,"type":41},"2026-03-03",{"date":575,"type":24},"2026-03-11",{"date":114,"type":24},{"name":578,"class":579},"SF Research Institute, Inc.","NETWORK",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":18,"sex":19,"minAge":308,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":25,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":620},"100622066","time-restricted-eating-in-combination-with-a-low-glycaemic-index-diet-on-cognitive-function-biological-ageing-and-metabolic-health-in-perimenopause-and-menopause-100622066","NCT07378787","Time-Restricted Eating in Combination With a Low Glycaemic Index Diet on Cognitive Function, Biological Ageing and Metabolic Health in Perimenopause and Menopause.","The Effect of Time-Restricted Eating in Combination With a Low Glycaemic Index Diet on Cognitive Function, Markers of Biological Age and Metabolic Health in Late-Perimenopausal and Menopausal Women: a Randomized Controlled Trial. The NutriAge Trial.","NutriAge","Inclusion Criteria:\n\n* Women in late perimenopausal or menopausal status Note: Late perimenopause is defined as two or more skipped cycles and at least 60 days of amenorrhea. Recent blood tests showing elevated FSH levels support eligibility for late perimenopause. Menopause is defined as 12 consecutive months without a menstrual cycle.\n* BMI ≥23 kg\u002Fm2\n* Age 45-75 years old\n* If using any medication, the dose should be stable for the previous 12 months\n* Able to use technology and follow the dietary plan\n\nExclusion Criteria:\n\n* Diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD). Note: (Self-reported memory complaints are allowed).\n\n  * On hormone replacement therapy (HRT)\n  * Medical conditions that significantly affect cognitive or metabolic function including diagnosis of type 1 diabetes, severe metabolic disorders, cardiovascular disease, or neurodegenerative conditions, diagnosed eating disorders or severe mental health conditions.\n  * Currently enrolled in another intervention.\n  * Severe food allergies or dietary restrictions that would prevent adherence to the study diet.\n  * History of substance abuse.","75 Years",{"count":452,"type":24},[27],"The goal of this randomised controlled trial is to investigate whether Time-Restricted Eating (TRE) combined with a Low Glycaemic Index Mediterranean Diet can improve cognitive function, metabolic health, and biological ageing in late perimenopausal and menopausal women aged 45-75 years with a BMI ≥23 kg\u002Fm². It will consist of a 12-week intervention followed by a 12 week follow-up period.\n\nResearchers will compare a group following the 16:8 time-restricted eating schedule and Low Glycaemic Index Mediterranean Diet to a control group (waiting list) receiving no dietary or meal-timing instructions to determine if these dietary strategies influence cognitive function, assessed via brain-derived neurotropic factor (BDNF) and cognitive function tests, metabolic outcomes, biological age, the gut microbiome, tender and swollen joint count and global health.\n\nParticipants will:\n\nFollow a 16:8 time-restricted eating schedule (eating within an 8-hour window and fasting for 16 hours) if assigned to the intervention group.\n\nAdhere to a tailored Low Glycaemic Index Mediterranean Diet and track meals using the Nutrium app.\n\nAttend study visits at the University of Nicosia at Week 0, Week 12, and Week 24 for various assessments.\n\nProvide biological samples, including blood samples at five specific intervals and stool samples at Week 0 and Week 12.\n\nComplete multiple questionnaires regarding diet, lifestyle, sleep quality, physical activity, tender and swollen joints, and quality of life.\n\nUndergo physical and cognitive assessments, such as CNS Vital Signs tests, blood pressure measurements, and body composition analysis.\n\nThe two groups will be compared to understand if the intervention improves outcomes and can thus be applied in this population group.",[593,30,31],"Late-perimenopause",[595,75,596,597,136,598,599,600,81,220,601,602,603,134,604,605,606,607,608,609,610],"Peri-menopause","intermittent fasting","low glycaemic-index diet","time-restricted eating","biological ageing","metabolic markers","tender joints","swollen joints","nutrition","Mediterranean diet","GlycanAge","randomized controlled trial","BDNF","insulin resistance","middle-aged","global health","2026-01-23",{"date":613,"type":41},"2026-01-30",{"date":615,"type":41},"2026-01-17",{"date":617,"type":24},"2029-01-20",{"name":619,"class":48},"University of Nicosia",2,{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":19,"minAge":308,"maxAge":58,"enrollmentInfo":628,"targetDuration":4,"studyType":25,"phases":630,"briefSummary":631,"conditions":632,"keywords":633,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":648,"locationsCount":96},"100612262","impact-of-funcional-exercise-and-supplementation-in-perimenopausal-womens-health-100612262","NCT07251296","Impact of Funcional Exercise and Supplementation in Perimenopausal Women's Health","Effects of a Nutritional Supplement and Physical Exercise on the Psycho-emotional, Cognitive, Functional, and Neuroendocrine Health of Perimenopausal Women.","Inclusion Criteria:\n\n* Women aged between 45 and 65 years.\n* In the menopausal transition (defined by irregular menstrual cycles and typical symptoms within the past year) or postmenopause.\n* Score ≥ 8 on the Menopause Rating Scale (MRS), indicating moderate menopausal symptom intensity.\n* Regular nighttime sleep and not engaged in shift work.\n* Low physical activity level: less than 150 minutes per week of moderate or vigorous physical activity, as assessed by the short-form IPAQ or a similar questionnaire.\n* Body mass index (BMI) between 18.5 and 35 kg\u002Fm².\n* Sufficient functional and cognitive capacity to participate in supervised physical exercise and follow the study protocol.\n* Signed informed consent and availability to attend all scheduled sessions and assessments.\n\nExclusion Criteria:\n\n* Current or recent (within the last 3 months) use of hormone replacement therapy (HRT).\n* Surgical, induced, or early menopause (before age 40).\n* Current treatment with medications that may affect mood, sleep, or vasomotor symptoms, including: antidepressants (SSRIs, SNRIs, tricyclics); anxiolytics or hypnotics; phytoestrogens, isoflavones, or other over-the-counter hormonal supplements.\n* Medical diagnosis of severe or uncontrolled chronic diseases, including cardiovascular, respiratory (particularly sleep apnea), metabolic, active oncological, neurological, severe autoimmune, or psychiatric disorders.\n* Regular use within the past 3 months of nutritional or sports supplements that may interfere with study outcomes (e.g., creatine, protein, omega-3, adaptogens, etc.).\n* Medical contraindications for moderate-to-vigorous physical exercise, as determined by the PAR-Q+ questionnaire and\u002For updated medical report.\n* Simultaneous participation in another clinical trial or intervention program involving drugs, supplements, or structured physical exercise of any kind.\n* Known allergy or intolerance to any component of the nutritional supplement to be administered.",{"count":629,"type":24},90,[27],"The goal of this clinical trial is to learn whether a natural-origin nutritional supplement, combined with a functional exercise program, can improve psycho-emotional, cognitive, functional, and neuroendocrine health in perimenopausal women. The study will also help determine the safety of this combined intervention.\n\nThe main questions it aims to answer are:\n\n* Does the combined intervention improve mood, sleep quality, menopausal symptoms, and cognitive performance?\n* Does it enhance physical function and neuroendocrine regulation?\n\nResearchers will compare the supplement to a placebo. All participants will follow the same supervised functional exercise program.\n\nParticipants will:\n\n* Take a daily nutritional supplement or placebo for 10 weeks\n* Attend three weekly supervised functional exercise sessions (45-60 minutes each)\n* Complete pre- and post-intervention evaluations including questionnaires, physical and cognitive tests, and blood samples for biomarker analysis.",[31,401],[31,634,635,636,637,638,496,639,640,641,642],"nutritional supplement","Functional exercise","Psycho-emotional health","Cognitive function","Non-pharmacological interevention","Physical function","variable resistance training","Neuroendocrine biomarkers","Sleep and mood regulation","2025-12-15",{"date":645,"type":41},"2025-12-22",{"date":643,"type":41},{"date":202,"type":24},{"name":649,"class":48},"University of Valencia",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":19,"minAge":308,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":25,"phases":659,"briefSummary":660,"conditions":661,"keywords":663,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":96},"100545047","no-time-to-pause-physical-activity-to-improve-health-of-midlife-hispanic-women-100545047","NCT06376812","No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women","No Time to Pause: Physical Activity to Improve Health and Well-being of Midlife Hispanic Women During the Menopausal Transition","Inclusion Criteria:\n\n1. Female\n2. Hispanic by self-report\n3. Able to speak and read English\n4. Sedentary\n5. Age 45-50\n6. Diagnosed with elevated blood pressure or objectively measured systolic blood pressure 120-139 mmHg and\u002For diastolic blood pressure 80-89 mmHg averaged from ≥ 2 measures on ≥ 2 outpatient visits\n7. Symptoms consistent with the menopause transition (persistent difference of ≥7 days in the length of consecutive cycles; persistence is defined as recurrence within 10 cycles of the first variable length cycle)\n8. Apparently healthy\n9. Self-reported ability to engage in moderate intensity physical activity\n10. Access to a smart device that is compatible with a Fitbit application\n\nExclusion Criteria:\n\n1. Self-reported physical activity of ≥150 minutes per week\n2. Answered yes to any question on the Physical Activity Readiness (PAR-Q+) questionnaire\n3. Post-menopausal (12-months without a menstrual cycle)\n4. Diagnosed hypertension\n5. Cardiovascular, respiratory, neurological, renal, endocrine, gastrointestinal and\u002For psychiatric diseases, or any cancers\n6. Previous hysterectomy, oophorectomy, and\u002For uterine ablation\n7. Medication to treat hypertension, elevated glucose, cholesterol, depression, anxiety, and insomnia\n8. Hormonal medication via any route or implants\n9. Tamoxifen\n10. Pregnant, planning to become pregnant, or breastfeeding\n11. Planning to move out of the Galveston\u002FHouston area in the next 18 months\n12. Current participation in another physical activity study or program","50 Years",{"count":128,"type":24},[27],"This study will test the effects of a physical activity intervention among midlife Hispanic women.",[662,31],"Elevated Blood Pressure",[664,665,666,667,668],"Physical activity","Women's health","Minority health","Behavior change","Hypertension prevention","2025-12-01",{"date":671,"type":41},"2025-12-08",{"date":673,"type":24},"2027-01-20",{"date":675,"type":24},"2029-01",{"name":677,"class":48},"The University of Texas Medical Branch, Galveston",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":183,"enrollmentInfo":684,"targetDuration":4,"studyType":25,"phases":686,"briefSummary":687,"conditions":688,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":96},"100579627","melatonin-effects-on-cardiovascular-disease-mechanisms-in-midlife-women-a-randomized-clinical-trial-100579627","NCT06826755","Melatonin Effects on Cardiovascular Disease Mechanisms in Midlife Women: A Randomized Clinical Trial","Inclusion Criteria\n\n* Age 40-55 years old\n* Female individuals with intact uterus and at least one ovary\n* Hypertension\n\n  o Defined as a prior diagnosis of hypertension, use of antihypertensive agents, or office SBP\u002FDBP ≥130\u002F80 mmHg\n* On stable medical regimen (≥ 2 months) if taking other medications\n\nExclusion Criteria\n\n* Prescription sleeping medications or melatonin supplementation\n* Pregnant or lactating\n* Use of tobacco, nicotine or vaping products\n* Night shift work\n* On prescription aspirin\n* Severe lactose intolerance\n* History of substance use disorder\n* History of suicidal ideation\n* History of clinically diagnosed anemia (within the past 5 years) or low hemoglobin levels (\\\u003C11.6 g\u002FdL) within the past 12 months\n* Active cancer\n* Severe daytime sleepiness (score \\>15 at the Epworth Sleepiness Scale \\[ESS\\])81\n* Current or recent (within the past 2 months) participation in other research studies at the discretion of study investigators\n* Inability to provide written consent and\u002For to speak and read English\n* Any other medical, geographic, or social factor making study participation impractical",{"count":685,"type":24},70,[27],"The purpose of this research is to study the effects of 12 weeks of melatonin supplementation compared to placebo in women who are in the menopause transition (perimenopause) and have high blood pressure.",[31,689],"Hypertension","2025-11-19",{"date":692,"type":41},"2025-11-24",{"date":694,"type":41},"2025-05-23",{"date":696,"type":24},"2027-01",{"name":698,"class":48},"Mayo Clinic",{"id":700,"slug":701,"hasResults":12,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":4,"eligibilityCriteria":705,"healthyVolunteers":12,"sex":19,"minAge":283,"maxAge":183,"enrollmentInfo":706,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":708,"conditions":709,"keywords":716,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":96},"100594705","a-trial-to-investigate-the-accuracy-of-a-wearable-device-in-collecting-data-related-to-perimenopausal-symptoms-in-women-100594705","NCT07022925","A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women","An Observational Virtual Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women","Inclusion Criteria:\n\n1. Females between 35-55 years of age, inclusive\n2. Self-reported perimenopausal women experiencing hot flushes or night sweats\n3. Individuals of child-bearing potential must confirm they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. Acceptable methods of birth control include:\n\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence\n4. Agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, supplements\u002Fmedications, and sleep\n5. Provided voluntary and informed consent to participate in the study\n6. Generally healthy as determined by medical history with no unstable diagnosed medical conditions\n\nExclusion Criteria:\n\n1. Allergy or sensitivity to adhesive used for wearing the investigational device\n2. Self-reported use of a pacemaker\n3. Self-reported unstable diagnosed anxiety disorder\n4. Self-reported sleep disorder requiring medical treatment\n5. Self-reported skin conditions or sensitive skin around the area of application\n6. Self-reported surgery in the past three months or individuals who have planned surgery during the course of the study\n7. Alcohol intake average of ˃1 standard drink per day\n8. Alcohol or drug abuse within the last 12 months that has required treatment\n9. Current use of prescribed and\u002For over-the-counter (OTC) medications\u002Fsupplements that may impact data recorded by the investigational device (see Section 7.3)\n10. Participation in other clinical research studies 30 days prior to screening\n11. Individuals who are unable to give informed consent\n12. Any other condition or lifestyle factor, that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":707,"type":24},110,"The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms via an app. The main question it aims to answer is:\n\nWhat is the accuracy of the developed algorithm from the investigational device compared to daily self-report via an app in characterizing perimenopausal symptoms?\n\nParticipants will be asked to wear IndentifyHer's wearable non-invasive sensor and complete a daily electronic diary and questionnaires on stress, anxiety, and sleep.",[31,710,711,217,712,713,714,715],"Perimenopausal Depression","Perimenopausal Insomnia","Menopausal Depression","Menopausal Hot Flashes","Menopausal and Postmenopausal Disorders","Menopausal Vasomotor Symptoms",[30,31,717,718,719,720,721],"Vasomotor symptoms","Hot flashes","IdentifyHer","Peri","Perimenopausal symptoms","2025-09-17",{"date":724,"type":41},"2025-09-18",{"date":726,"type":41},"2025-07-04",{"date":728,"type":24},"2025-10",{"name":730,"class":95},"IdentifyHer Limited"]